Abstract
To assess whether adding or switching to sulfonylureas is associated with an increased risk of myocardial infarction, ischaemic stroke, cardiovascular death, all cause mortality, and severe hypoglycaemia, compared with remaining on metformin monotherapy in patients with type 2 diabetes. Population based cohort study. General practices contributing data to the UK Clinical Practice Research Datalink. Patients with type 2 diabetes initiating metformin monotherapy between 1998 and 2013. Using the prevalent new-user cohort design we matched 1:1 patients adding or switching to sulfonylureas with those remaining on metformin monotherapy on high-dimensional propensity score, haemoglobin A1c, and number of previous metformin prescriptions. The two groups were compared using Cox proportional hazards models to estimate adjusted hazard ratios and 95% confidence intervals for the study outcomes. Among 77 138 metformin initiators, 25 699 added or switched to sulfonylureas during the study period. During a mean follow-up of 1.1 years, sulfonylureas were associated with an increased risk of myocardial infarction (incidence rate 7.8 v 6.2 per 1000 person years, hazard ratio 1.26, 95% confidence interval 1.01 to 1.56), all cause mortality (27.3 ...Continue Reading
Citations
Jun 5, 2019·Diabetologia·Shiu Lun Au YeungC Mary Schooling
Jul 13, 2019·Diabetes, Obesity & Metabolism·Antonio NicolucciStuart Pocock
Oct 10, 2019·Diabetes, Obesity & Metabolism·Antonios DourosSamy Suissa
Aug 5, 2020·Diabetologia·Shan LuoShiu Lun Au Yeung
Sep 12, 2019·Communications Biology·Jie V ZhaoC Mary Schooling
Jun 27, 2019·Drugs -- Real World Outcomes·Hui-Min Diana LinSamy Suissa
Aug 7, 2019·Journal of Hypertension·Shiu Lun Au YeungCatherine M Schooling
Aug 1, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Carlo Bruno GiordaFranco Cavalot
Aug 22, 2018·Nutrients·Alex LubranskyBernard J Venn
Jul 18, 2019·Journal of General and Family Medicine·Masayuki Ikeda, Rumiko Shimazawa
Mar 12, 2020·Clinical Diabetes and Endocrinology·Wayne WengTodd Hobbs
Jul 23, 2020·Frontiers in Pharmacology·Jonni Hazeline Koia, Peter Shepherd
Aug 7, 2019·Cardiovascular Diabetology·Aaron Y KlugerPeter A McCullough
Aug 18, 2020·Cardiovascular Endocrinology & Metabolism·Dennis Bruemmer, Steven E Nissen
Aug 22, 2020·Journal of Lipid and Atherosclerosis·Laura J MereweatherLisa C Heather
Jan 10, 2021·Scientific Reports·Desye GebrieTsegahun Manyazewal
Jan 28, 2021·Diabetes, Obesity & Metabolism·So-Hee ParkJu-Young Shin
Nov 26, 2020·Journal of Clinical Medicine·Jordan GuillotJulien Bezin
Dec 22, 2020·Terapevticheskiĭ arkhiv·N A ChernikovaK A Ryzhikova
Jan 12, 2020·Communications Biology·Jie V ZhaoC Mary Schooling
Jun 4, 2021·Current Cardiology Reports·Ben Alencherry, Dennis Bruemmer
Aug 3, 2021·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Desye GebrieEyasu Makonnen
Jul 13, 2021·Diabetes, Obesity & Metabolism·Karine SuissaLaurent Azoulay
Aug 27, 2021·Frontiers in Nutrition·Mark CucuzzellaDiana Isaacs
Aug 15, 2021·Cardiovascular Research·Gianluigi SavareseStefan D Anker
Dec 7, 2021·Diabetes Spectrum : a Publication of the American Diabetes Association·Timothy S BaileyEugene E Wright
Jan 9, 2022·Scientific Reports·Chen-Yi YangHuang-Tz Ou